Lipid metabolic pathways as lung cancer therapeutic targets: A computational study

International Journal of Molecular Medicine

Volumn 29, Issue 4, 2012, Pages 519-529

  Yano, Kojiro ^a  

^a OSAKA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Lipid metabolism; Lung cancer; Microarray

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEAR FACTOR Y; SCATTER FACTOR RECEPTOR;

ARTICLE; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIVISION; CELL MIGRATION; DNA REPAIR; DNA REPLICATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; HUMAN; LIPID METABOLISM; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; BRCA1 PROTEIN; CCAAT-BINDING FACTOR; COMPUTER SIMULATION; DNA REPAIR; DNA REPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPID METABOLISM; LUNG NEOPLASMS; MEVALONIC ACID; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84858255021     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.876     Document Type: Article

References (72)

1. Stinchcombe TE and Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6: 233-241, 2009.
2. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007. (Pubitemid 350002184)
3. Bean J, Brennan C, Shih, JY, Riely, G, Viale A, Wang L, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
4. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-9487, 2008.
5. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al: The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100: 134-139, 2008. (Pubitemid 351480564)
6. Khurana V, Bejjanki HR, Caldito G and Owens MW: Statins reduce the risk of lung cancer in humans: a large case-control study of us veterans. Chest 131: 1282-1288, 2007. (Pubitemid 46762329)
7. Taylor ML, Wells BJ and Smolak MJ: Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 17: 259-268, 2008.
8. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, et al: Incidence of cancer and statin usage-record linkage study. Int J Cancer 126: 279-284, 2010.
9. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA and Dimitroulakos J: Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 129: 631-641, 2003. (Pubitemid 37452629)
10. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA and Dimitroulakos J:Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11: 2398-2407, 2005. (Pubitemid 40490201)
11. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al: Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61: 4885-4891, 2001. (Pubitemid 32691906)
12. Park IH, Kim JY, Jung JI and Han JY: Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 28: 791-799, 2010.
13. Buhaescu I and Izzedine H: Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40: 575-584, 2007. (Pubitemid 46829082)
14. Pike LJ and Casey L: Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 41: 10315-10322, 2002. (Pubitemid 34856457)
15. Ringerike T, Blystad FD, Levy FO, Madshus IH and Stang E: Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci 115: 1331-1340, 2002. (Pubitemid 34272497)
16. Parmigiani G, Garrett-Mayer E, Anbazhagan R and Gabrielson E: A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 10: 2922-2927, 2004. (Pubitemid 38619666)
17. Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, et al: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62: 3005-3008, 2002. (Pubitemid 34602385)
18. Rhodes DR, Yu J, Shanker, K, Deshpande N, Varambally R, Ghosh D, et al:Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101: 9309-9314, 2004. (Pubitemid 38812872)
19. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 3: e1651, 2008.
20. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al: NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 37: D885-D890, 2009.
21. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4: P3, 2003.
22. Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
23. Rhee SY, Wood V, Dolinski K and Draghici S: Use and misuse of the gene ontology annotations. Nat Rev Genet 9: 509-515, 2008. (Pubitemid 351861540)
24. Benjamini Y, Drai D, Elmer G, Kafkafi N and Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284, 2001. (Pubitemid 33000466)
25. Berger SI, Posner JM and Ma'ayan A: Genes2networks: connecting lists of gene symbols using mammalian protein interactions databases. BMC Bioinformatics 8: 372, 2007.
26. Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK and Boylan AM: CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol 38: 671-678, 2008. (Pubitemid 351841568)
27. Casabiell X, Zugaza JL, Pombo CM, Pandiella A and Casanueva FF: Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. Exp Cell Res 205: 365-373, 1993. (Pubitemid 23192144)
28. McKenzie KE, Bandyopadhyay GK, Imagawa W, Sun K and Nandi S: Omega-3 and omega-6 fatty acids and PGE2 stimulate the growth of normal but not tumor mouse mammary epithelial cells: evidence for alterations in the signaling pathways in tumor cells. Prostaglandins Leukot Essent Fatty Acids 51: 437-443, 1994.
29. Mollerup S and Haugen A: Differential effect of polyunsaturated fatty acids on cell proliferation during human epithelial invitro carcinogenesis: involvement of epidermal growth factor receptor tyrosine kinase. Br J Cancer 74: 613-618, 1996. (Pubitemid 26279059)
30. Bennis F, Favre G, Gaillard FL and Soula G: Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55: 640-645, 1993. (Pubitemid 23328952)
31. Fukuchi J, Song C, Ko AL and Liao S: Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids 68: 685-691, 2003. (Pubitemid 37075930)
32. Forman BM, Ruan B, Chen J, Schroepfer GJ and Evans RM: The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 94: 10588-10593, 1997.
33. Terano T, Shiina T, Noguchi Y, Tanaka T, Tatsuno I, SaitoY, etal:Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells. J Atheroscler Thromb 5: 1-6, 1998.
34. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, etal: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275: 30451-30457, 2000.
35. Shamma A, Takegami Y, Miki T, Kitajima S, Noda M, Obara T, etal: Rb regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 15: 255-269, 2009.
36. Kasayama S, Koga M, Kouhara H, Sumitani S, Wada K, Kishimoto T, et al: Unsaturated fatty acids are required for continuous proliferation of transformed androgen-dependent cells by fibroblast growth factor family proteins. Cancer Res 54: 6441-6445, 1994.
37. Renard CB, Askari B, Suzuki LA, Kramer F and Bornfeldt KE: Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells. Diabetologia 46: 1676-1687, 2003. (Pubitemid 38005330)
38. 2+ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid. J Biol Chem 272: 29546-29553, 1997.
39. Yun MR, Lee JY, Park HS, Heo HJ, Park JY, Bae SS, etal: Oleic acidenhances vascular smooth muscle cell proliferation via phosphatidylinositol 3-kinase/AKT signaling pathway. Pharmacol Res 54: 97-102, 2006. (Pubitemid 44038381)
40. Niki E: Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 47: 469-484, 2009.
41. Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA and Muzio G: Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact 165: 239-250, 2007. (Pubitemid 46237619)
42. Maehle L, Lystad E, Eilertsen E, Einarsdottr E, Hstmark AT and Haugen A: Growth of human lung adenocarcinoma in nude mice is influenced by various types of dietary fat and vitaminE. Anticancer Res 19: 1649-1655, 1999. (Pubitemid 29392718)
43. Matuoka K and Chen KY: Transcriptional regulation of cellular ageing by the CCAAT box-binding factor CBF/NF-Y. Ageing Res Rev 1: 639-651, 2002. (Pubitemid 38340322)
44. Clarke SD: Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr 131: 1129-1132, 2001.
45. Reed BD, Charos AE, Szekely AM, Weissman SM and Snyder M: Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. PLoS Genet 4: e1000133, 2008.
46. Hu Q and Maity SN: Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes. J Biol Chem 275: 4435-4444, 2000. (Pubitemid 30094687)
47. Chabes AL, Bjrklund S and Thelander L: S phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem 279: 10796-10807, 2004. (Pubitemid 38372692)
48. Koessler H, Kahle J, Bode C, Doenecke D and Albig W: Human replication-dependent histone H3 genes are activated by a tandemly arranged pair of two CCAAT boxes. Biochem J 384: 317-326, 2004. (Pubitemid 39656244)
49. Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, et al: Cyclin-dependent kinase activation and S-phase induction of the cyclin B1 gene are linked through the CCAAT elements. Cell Growth Differ 8: 811-820, 1997. (Pubitemid 27287812)
50. Jin S, Fan F, Fan W, Zhao H, Tong T, Blanck P, et al: Transcription factors OCT-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene 20: 2683-2690, 2001. (Pubitemid 32525299)
51. Manni I, Mazzaro G, Gurtner A, Mantovani R, Haugwitz U, Krause K, et al: NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem 276: 5570-5576, 2001.
52. Kim HT, Lee JE, Shin ES, Yoo YK, Cho JH, Yun MH, et al: Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 26: 5972-5979, 2008.
53. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, KoutsopoulosA, et al: Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 3: e3695, 2008.
54. Volm M and Koomgi R: Relevance of proliferative and proapoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 82: 1747-1754, 2000. (Pubitemid 30229588)
55. Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, et al: Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Anticancer Res 20: 505-510, 2000. (Pubitemid 30189710)
56. Zhou Q, Su Y and Bai M: Effect of antisense RNA targeting polo-like kinase 1 on cell growth in A549 lung cancer cells. J Huazhong Univ Sci Technolog Med Sci 28: 22-26, 2008.
57. Spnkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmller M, et al:Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21: 3162-3171, 2002. (Pubitemid 34548087)
58. Tan DF, Huberman JA, Hyland A, Loewen GM, Brooks JS, Beck AF, et al: MCM2-a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer 1: 6, 2001.
59. Thompson D, Seal S, Schutte M, McGuffog L, Barfoot R, RenwickA, et al: A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 15: 2542-2545, 2006. (Pubitemid 46048319)
60. Cybulski C, Masojc B, Oszutowska D, Jaworowska E, Grodzki T, Waloszczyk P, et al: Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 29: 762-765, 2008. (Pubitemid 351494163)
61. Volm M, Koomgi R and Rittgen W: Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer 79: 294-299, 1998. (Pubitemid 28262217)
62. Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K, et al: Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): prognostic implication. Lung Cancer 65: 223-229, 2009.
63. Neville-Webbe HL, Evans CA, Coleman RE and Holen I: Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 27: 92-103, 2006.
64. Gunning WT, Kramer PM, Lubet RA, Steele VE, End DW, Wouters W and Pereira MA: Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. Clin Cancer Res 9: 1927-1930, 2003. (Pubitemid 36554621)
65. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas, GA and Leonard RC: The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46: 669-677, 2007. (Pubitemid 46911908)
66. Doisneau-Sixou SF, Cestac P, Faye JC, Favre G and Sutherland RL: Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCM-7 breast cancer cell-cycle progression. Int J Cancer 106: 789-798, 2003. (Pubitemid 37006315)
67. Bruemmer D, Yin F, Liu J, Kiyono T, Fleck E, Herle AV, et al: Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Eur J Pharmacol 462: 15-23, 2003. (Pubitemid 36183730)
68. Fan W, Jin S, Tong T, Zhao H, Fan F, Antinore MJ, et al: BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem 277: 8061-8067, 2002. (Pubitemid 34968259)
69. Chae HD, Yun J, Bang YJ and Shin DY: Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions. Oncogene 23: 4084-4088, 2004. (Pubitemid 38747939)
70. Salsi V, Caretti G, Wasner M, Reinhard W, Haugwitz U, Engeland K, et al: Interactions between P300 and multiple NF-Y trimers govern cyclin b2 promoter function. J Biol Chem 278: 6642-6650, 2003. (Pubitemid 36800650)
71. Goodarzi H, Elemento O and Tavazoie S: Revealing global regulatory perturbations across human cancers. Mol Cell 36: 900-911, 2009.
72. Yamanaka K, Mizuarai S, Eguchi T, Itadani H, Hirai H and Kotani H: Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics 94: 219-227, 2009.